Marks Peter Ashley
Known title: DirectorCIK: 0002127888
Marks Peter Ashley's purchase track record
Marks Peter Ashley has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2026 | ATHE | $24K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ATHE | ▲ Buy | Open Market | 47,620 | $24K | 8/31/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Alterity CEO speaks at ASX SMIDcaps Conference
Alterity Therapeutics CEO spoke at the ASX SMIDcaps Conference, sharing insights on the company's progress. The appearance highlights ongoing engagement with investors and industry peers. Shares are currently trading near a key support level at $4.50.
Alterity CEO speaks at ASX SMIDcaps Conference. Alterity Therapeutics CEO spoke at the ASX SMIDcaps Conference, sharing insights on the company's progress. The appearance highlights ongoing engagement with investors and industry peers. Shares are currently trading near a key support level at $4.50.